Choosing an antibody supplier from a trade-show conversation is hard. A banner can promise "full-service antibody development," but visitors rarely get more than a few minutes to judge whether a vendor can actually take a project from a raw sequence to a manufacturable, IVD-ready or engineered antibody — or whether the work will bounce between three different subcontractors along the way.
This article covers what BrightMD Fair China 2026 is, why Sekbio is exhibiting, what "one-stop" antibody engineering actually means in practical terms, and what visitors can expect at Sekbio's booth in Shenzhen this September.
1. What Is BrightMD Fair China 2026?
BrightMD Fair China 2026 (深圳国际高性能医疗器械展暨创新医药展) is an international high-performance medical device and innovative pharmaceutical exhibition taking place September 21-23, 2026, at the Shenzhen World Exhibition & Convention Center (Futian), Hall 1. The show is organized by the Shenzhen Medical Device Industry Association and the National High-Performance Medical Device Innovation Center, under the theme "New Quality Medical Devices, A Smart New Chapter" (新质药械 智启新篇).
The exhibition brings together three groups that rarely share a floor at the same scale: finished-device manufacturers, innovative pharmaceutical companies, and the upstream raw-material and biological-reagent suppliers — antibody developers included — that both groups depend on. For an antibody manufacturer like Sekbio, that mix matters: it's an opportunity to meet both IVD device makers sourcing antibody pairs and pharmaceutical teams evaluating antibody engineering partners for therapeutic-stage programs, in the same three days.
- Dates: September 21-23, 2026
- Venue: Shenzhen World Exhibition & Convention Center (Futian), Hall 1
- Organizers: Shenzhen Medical Device Industry Association; National High-Performance Medical Device Innovation Center
- Theme: "New Quality Medical Devices, A Smart New Chapter"
2. Why Sekbio Is Exhibiting
Sekbio is headquartered in Shenzhen, and BrightMD Fair China 2026 is being held in our home city — which makes it a natural venue to meet local and international partners face to face rather than over email threads and video calls. Shenzhen's high-performance medical device cluster has grown quickly, and a growing share of that growth depends on a reliable, quality-certified upstream antibody supply chain that most device teams never see directly.
Our reason for exhibiting is straightforward: give current and prospective partners a place to bring a real project — a sequence that needs humanizing, an antibody pair that needs pairing validation, an expression bottleneck that needs solving — and walk away with a concrete next step, not a brochure. Whether you already work with Sekbio or are evaluating antibody development partners for the first time, the booth is set up for working conversations, not just introductions.
"A one-stop antibody engineering solution isn't about doing everything under one roof for convenience — it's about controlling quality at every handoff point, from sequence review to the final validated batch." — Dr. Chen, Senior Antibody Scientist, Sekbio
That philosophy shapes how we built our service portfolio, and it's the core message we bring to BrightMD Fair China 2026: reliable antibody development services and antibody engineering, delivered as one coordinated project rather than a chain of separate vendors.
3. What Is a One-Stop Antibody Engineering Solution?
Antibody engineering is the set of molecular techniques used to modify an antibody's sequence or format after initial discovery — improving its affinity, changing its structure, reducing immunogenicity, or converting it into a different functional format — so that it performs reliably in its intended application, whether that's a diagnostic assay or a therapeutic program. A one-stop antibody engineering solution means these techniques, plus the expression and manufacturing steps around them, are handled by a single accountable team under one quality system, instead of being split across a sequencing vendor, an engineering CRO, and a separate expression facility.
At Sekbio, this one-stop scope covers four core engineering capabilities, alongside our underlying expression and cell-line infrastructure:
- Humanized Antibody Development — CDR grafting and framework optimization to convert mouse or rabbit antibodies into humanized monoclonal antibodies
- Affinity Maturation — library construction and screening to improve binding affinity beyond the parental clone
- Format Conversion — converting between IgG, Fab, scFv, and VHH formats to match assay or manufacturing requirements
- Bispecific Antibody Engineering — dual-targeting antibody design, including correct heavy/light chain pairing
IVD Application Note
Most IVD antibody-pair projects never need the full engineering stack above — a validated hybridoma-derived pair is often enough. Engineering steps like humanization or affinity maturation become relevant when a partner needs to improve an existing clone's sensitivity, resolve cross-reactivity, or convert a research-grade antibody into a manufacturable format for scale-up.
What ties these capabilities together operationally is that every engineered antibody intermediate — regardless of which service triggered the project — moves through the same antibody engineering platform and the same CHO/HEK293 expression infrastructure, under a single ISO 13485-certified quality system.
4. Sekbio's End-to-End Antibody Development Workflow
In practice, "one-stop" is a workflow, not a slogan. The table below walks through the stages a typical project moves through, from an initial sequence or clone to validated production output, along with the timelines partners can generally expect at each stage.
| Stage | What Happens | Typical Timeline |
|---|---|---|
| Sequence & Feasibility Review | Sequence analysis, developability assessment, and project scoping | 3-5 business days |
| CHO / HEK293 Transient Expression Screening | Small-scale expression to confirm titer and binding activity | As fast as 7 days |
| Antibody Engineering (as needed) | Humanization, affinity maturation, format conversion, or bispecific design | Scoped per project |
| Full Monoclonal Antibody Development | Sequence to a validated, application-ready monoclonal antibody | 8-12 weeks end-to-end |
| Stable Cell Line Development | Establishing a proprietary, high-yield CHO production cell line (up to 2.4 g/L) | 2-3 months |
| Batch Production & QC | ISO 13485-controlled manufacturing with lot release testing | Per contract volume |
Because these stages run inside one organization, a project that starts as "just a CHO expression screen" can move directly into monoclonal antibody development or a stable cell line program without a data handoff between vendors — the same team that ran the sequence review already has the developability data on file.
5. What to Expect at Sekbio's Booth
Sekbio's team will be on-site for all three days of BrightMD Fair China 2026, ready to walk through active or prospective projects in as much technical depth as a visitor wants. Expect to see and discuss:
- Sekbio's antibody pair catalogue for ELISA, CLIA, and lateral flow platforms
- Live discussion of antibody engineering case scopes — humanization, affinity maturation, format conversion, bispecific design
- CHO and HEK293 expression data and stable cell line development parameters
- ISO 13485 and CE Marking documentation for partners evaluating quality systems
Pro Tip: Book Your Booth Meeting in Advance
Trade show schedules fill up quickly, especially for technical deep-dives. To guarantee dedicated time with Sekbio's antibody development team, email info@sekbio.com with a short project background before September 21, 2026.
If you can't make it to Shenzhen this September, the same team and the same antibody engineering platform are reachable year-round through Sekbio's contact page — the booth conversation is simply the fastest way to start.
6. Frequently Asked Questions — BrightMD Fair China 2026
What is BrightMD Fair China 2026?
BrightMD Fair China 2026 (深圳国际高性能医疗器械展暨创新医药展) is an international high-performance medical device and innovative pharmaceutical exhibition held September 21-23, 2026, at the Shenzhen World Exhibition & Convention Center (Futian), Hall 1. The event is organized by the Shenzhen Medical Device Industry Association and the National High-Performance Medical Device Innovation Center under the theme "New Quality Medical Devices, A Smart New Chapter," bringing together device manufacturers, pharmaceutical innovators, and upstream raw-material and antibody suppliers from China and abroad.
Where and when is Sekbio exhibiting at BrightMD Fair China 2026?
Sekbio will be on-site for the full three days of the show, September 21-23, 2026, at the Shenzhen World Exhibition & Convention Center in Futian District, Hall 1. Visitors can meet Sekbio's antibody development team in person to discuss antibody pair selection, custom antibody engineering, and CHO/HEK293 expression projects. To reserve a dedicated meeting slot, contact info@sekbio.com before the show.
What antibody development services will Sekbio showcase at the exhibition?
At BrightMD Fair China 2026, Sekbio will showcase its full antibody development portfolio: validated monoclonal antibody pairs for ELISA, CLIA, and lateral flow platforms, recombinant antigen production, CHO and HEK293 transient and stable expression services, and antibody engineering capabilities including humanization, affinity maturation, format conversion (IgG to Fab/scFv/VHH), and bispecific antibody design.
What is Sekbio's "one-stop" antibody engineering solution?
Sekbio's one-stop antibody engineering solution covers the full path from a starting sequence or hybridoma clone to a manufacturable antibody: CDR grafting and humanization, affinity maturation through library construction and screening, format conversion between IgG, Fab, scFv, and VHH, and bispecific antibody engineering. Because every step runs under one ISO 13485-certified quality system, clients avoid the delays and inconsistency of coordinating separate vendors for sequencing, engineering, expression, and cell line development.
How long does Sekbio's end-to-end antibody development process take?
Timelines depend on project scope. CHO or HEK293 transient expression screening can return results in as fast as 7 days. A full monoclonal antibody development project, from sequence to a validated antibody, typically runs 8-12 weeks end-to-end, while establishing a proprietary stable cell line generally takes 2-3 months. Projects requiring antibody engineering steps such as humanization or affinity maturation are scoped individually after an initial sequence and developability review.
How can I schedule a meeting with Sekbio at BrightMD Fair China 2026?
Email info@sekbio.com or call +86-135 9034 5917 to book a meeting slot before the show, or visit Sekbio's booth during the exhibition dates (September 21-23, 2026) at the Shenzhen World Exhibition & Convention Center, Futian, Hall 1. For a technical discussion ahead of time, visit Sekbio's antibody engineering platform page to review capabilities before your visit.
7. Summary
- BrightMD Fair China 2026 runs September 21-23, 2026, at the Shenzhen World Exhibition & Convention Center (Futian), Hall 1, under the theme "New Quality Medical Devices, A Smart New Chapter."
- Sekbio is exhibiting to give IVD and pharmaceutical partners direct, technical access to our antibody development and antibody engineering team — not just marketing material.
- A one-stop antibody engineering solution means humanization, affinity maturation, format conversion, and bispecific design all run under the same quality system as our expression and cell-line infrastructure.
- The end-to-end workflow spans sequence review, CHO/HEK293 expression screening, engineering as needed, and stable cell line development — typically 8-12 weeks for a full monoclonal antibody project.
- Visitors can book a meeting in advance by emailing info@sekbio.com, or simply stop by the booth during the three-day show.
Whether you're sourcing a validated antibody pair for an IVD assay or scoping an engineering project for a therapeutic-stage program, Sekbio's team will be at BrightMD Fair China 2026 ready to talk specifics. Explore our antibody products or antibody engineering platform ahead of the show, or reach out directly to schedule time in Shenzhen.